DW5124-R

**DW5124-R** is Daewon's reference-comparator fixed-dose oral dyslipidemia treatment used in a Phase 1 pharmacokinetic study alongside the investigational formulation DW5124. Available trial reporting identifies the combination pharmacokinetic analytes as pitavastatin and fenofibric acid, supporting a formulation containing **pitavastatin + fenofibrate**. Pitavastatin inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase to lower cholesterol synthesis, while fenofibrate is converted to fenofibric acid, a peroxisome proliferator-activated receptor alpha agonist that improves triglyceride-rich lipoprotein metabolism. The program is intended for mixed dyslipidemia, particularly patients whose LDL cholesterol is controlled with pitavastatin but who retain elevated triglycerides and low HDL cholesterol. ([newsthevoice.com](https://www.newsthevoice.com/news/articleView.html?idxno=41815))